结直肠癌早期免疫逃避:干细胞与瘤微环境之间的相互作用
Norihiro Goto1, Judith Agudo2, Ömer H Yilmaz3
1Joan and Sanford I. Weill Department of Medicine, Division of Gastroenterology & Hepatology, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA; Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA.
Trends in cancer
|May 17, 2025
概括
大肠直肠癌 (CRC) 的早期遗传和表观遗传变化会产生免疫抑制的瘤微环境,阻碍有效的免疫检查点阻塞 (ICB) 治疗. 了解这些早期免疫逃避事件对于开发新的CRC治疗非常重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 大多数结直肠癌 (CRC) 具有低突变负担和免疫冷的微环境,限制了免疫检查点阻塞 (ICB) 疗法的有效性.
- 晚期瘤中的免疫逃避机制各不相同,但有证据表明,免疫逃避在癌前病变中更早地产生.
研究的目的:
- 审查CRC中早期驱动突变和表观遗传变化如何建立免疫抑制微环境.
- 要突出细胞交叉声驱动免疫逃避和肝脏转移在CRC.
- 为改进CRC预防和治疗策略的开发提供信息.
主要方法:
- 文献综述侧重于结直肠癌发展的早期事件.
- 对CRC中免疫逃避背后的分子机制的分析.
- 检查瘤微环境中的细胞相互作用.
主要成果:
- 早期的驱动突变和表观遗传改变有助于CRC的免疫抑制微环境.
- 癌细胞,肌体细胞和免疫细胞之间的动态交叉促进免疫逃避和肝脏转移.
- 免疫逃生机制在CRC发育的早期建立,甚至在癌前病变中.
结论:
- 了解CRC早期免疫逃避事件对于改善治疗策略至关重要.
- 针对早期的分子和细胞变化可能会提高ICB治疗CRC的疗效.
- 对CRC癌前阶段的进一步研究可能会导致新的预防和治疗方法.
相关概念视频
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.2K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.2K
Renewal of Intestinal Stem Cells
2.5K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
2.5K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


